Search Results - "Chun, Guinevere"

A case report of multiple primary prostate tumors with differential drug sensitivity by Wilkinson, Scott, Harmon, Stephanie A., Terrigino, Nicholas T., Karzai, Fatima, Pinto, Peter A., Madan, Ravi A., VanderWeele, David J., Lake, Ross, Atway, Rayann, Bright, John R., Carrabba, Nicole V., Trostel, Shana Y., Lis, Rosina T., Chun, Guinevere, Gulley, James L., Merino, Maria J., Choyke, Peter L., Ye, Huihui, Dahut, William L., Turkbey, Baris, Sowalsky, Adam G.

“…Localized prostate cancers are genetically variable and frequently multifocal, comprising spatially distinct regions with multiple independently-evolving…”
Get full text

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer by Abdul Sater, Houssein, Marté, Jennifer L, Donahue, Renee N, Walter-Rodriguez, Beatriz, Heery, Christopher R, Steinberg, Seth M, Cordes, Lisa M, Chun, Guinevere, Karzai, Fatima, Bilusic, Marijo, Harmon, Stephanie A, Turkbey, Ismail Baris, Choyke, Peter L, Schlom, Jeffrey, Dahut, William L, Madan, Ravi A, Pinto, Peter A, Gulley, James L

“…BackgroundClinical trials have shown the ability of therapeutic vaccines to generate immune responses to tumor-associated antigens (TAAs). What is relatively…”
Get full text

Abstract 618: The morphologic effects of treatment with neoadjuvant enzalutamide and androgen deprivation therapy in high risk prostatic cancer: What the pathologist needs to know by Merino, Maria J., Dikoglu, Esra, Pinto, Peter, Turkbey, Baris, Dahut, William, Chun, Guinevere, Madan, Ravi A., Karzai, Fatima

“…Abstract Background: In this study we report the effects of neoadjuvant enzalutamide (enza) plus androgen deprivation therapy (ADT) in the prostatectomy…”
Get full text

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy by Wilkinson, Scott, Ye, Huihui, Karzai, Fatima, Harmon, Stephanie A., Terrigino, Nicholas T., VanderWeele, David J., Bright, John R., Atway, Rayann, Trostel, Shana Y., Carrabba, Nicole V., Whitlock, Nichelle C., Walker, Stephanie M., Lis, Rosina T., Abdul Sater, Houssein, Capaldo, Brian J., Madan, Ravi A., Gulley, James L., Chun, Guinevere, Merino, Maria J., Pinto, Peter A., Salles, Daniela C., Kaur, Harsimar B., Lotan, Tamara L., Venzon, David J., Choyke, Peter L., Turkbey, Baris, Dahut, William L., Sowalsky, Adam G.

“…Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation…”
Get full text

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response by Karzai, Fatima, Walker, Stephanie M, Wilkinson, Scott, Madan, Ravi A, Shih, Joanna H, Merino, Maria J, Harmon, Stephanie A, VanderWeele, David J, Cordes, Lisa M, Carrabba, Nicole V, Bright, John R, Terrigino, Nicolas T, Chun, Guinevere, Bilusic, Marijo, Couvillon, Anna, Hankin, Amy, Williams, Monique N, Lis, Rosina T, Ye, Huihui, Choyke, Peter L, Gulley, James L, Sowalsky, Adam G, Turkbey, Baris, Pinto, Peter A, Dahut, William L

“…For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite…”
Get full text

A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures by Karzai, Fatima, Madan, Ravi Amrit, Sowalsky, Adam G., Bilusic, Marijo, Chun, Guinevere, Cordes, Lisa M., Wilkinson, Scott C., Terrigino, Nicholas, Harmon, Stephanie, Pinto, Peter A., Choyke, Peter L., Turkbey, Baris, Gulley, James L., Dahut, William L.

“…Abstract only 368 Background: PCa is driven by androgen receptor (AR) signaling and neoadjuvant therapy with AR inhibitors offer an opportunity to improve cure…”
Get full text

Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer by Wilkinson, Scott, Ye, Huihui, Carrabba, Nicole, Atway, Rayann, Trostel, Shana Y., Hennigan, Thomas, Lake, Ross, Harmon, Stephanie, Chun, Guinevere, Turkbey, Baris, Pinto, Peter A., Choyke, Peter L., Karzai, Fatima, VanderWeele, David J., Kelly, Kathleen, Dahut, William L., Sowalsky, Adam G.

“…Abstract Background: Genetic alterations in lethal, metastatic prostate cancer include the loss of PTEN, translocation of the TMPRSS2 and ERG genes,…”
Get full text

Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis by Chen, Gang, VanderWeele, David James, Karzai, Fatima, Bilusic, Marijo, Al Harthy, Munjid, Arlen, Philip M., Theoret, Marc Robert, Rosner, Inger L., Chun, Guinevere, Owens, Helen, Couvillon, Anna, Hankin, Amy, Williams, Monique, Gulley, James L., Dahut, William L., Madan, Ravi Amrit

“…Abstract only e16536 Background: Docetaxel has become a standard of care for mCSPC. Enzalutamide and abiraterone have been proven to improve survival in…”
Get full text

A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI) by Karzai, Fatima, Madan, Ravi Amrit, VanderWeele, David James, Chun, Guinevere, Bilusic, Marijo, Cordes, Lisa M., Carrabba, Nicole, Wilkinson, Scott, Ye, Huihui, Harmon, Stephanie, Sowalsky, Adam G., Turkbey, Baris, Pinto, Peter A., Choyke, Peter L., Gulley, James L., Dahut, William L.

“…Abstract only 63 Background: Neoadjuvant therapy with novel androgen receptor inhibitors, like enza, offer an opportunity to improve cure rates in men with…”
Get full text

Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide by Sowalsky, Adam G., Wilkinson, Scott, Ye, Huihui, Harmon, Stephanie, Turkbey, Baris, Carrabba, Nicole, Atway, Rayann, Chun, Guinevere, VanderWeele, David James, Karzai, Fatima, Madan, Ravi Amrit, Pinto, Peter A., Choyke, Peter L., Dahut, William L.

“…Abstract only 61 Background: AR directed therapies are standard of care for metastatic prostate cancer, and their use for high-risk localized disease may…”
Get full text

Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy by Gulley, James L., Abdul Sater, Houssein, Marte, Jenn, Donahue, Renee Nicole, Walter Rodriguez, Beatriz, Heery, Christopher Ryan, Stern, Mark, Thompson, Debrah, Cordes, Lisa M., Chun, Guinevere, Karzai, Fatima, Bilusic, Marijo, Schlom, Jeffrey, Dahut, William L., Madan, Ravi Amrit, Pinto, Peter A.

“…Abstract only…”
Get full text

Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses by VanderWeele, David James, Turkbey, Baris, Karzai, Fatima, Harmon, Stephanie, Sowalsky, Adam G., Ye, Huihui, Wilkinson, Scott, Chun, Guinevere, Gold, Samuel A, Pinto, Peter A., Choyke, Peter L., Dahut, William L.

“…Abstract only…”
Get full text

Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial by VanderWeele, David James, Turkbey, Baris, Karzai, Fatima, Harmon, Stephanie, Sowalsky, Adam G., Ye, Huihui, Wilkinson, Scott, Chun, Guinevere, Gold, Samuel, Pinto, Peter A., Choyke, Peter L., Dahut, William L.

“…Abstract only 94 Background: Intensive androgen-targeted therapy improves survival for patients with androgen naive metastatic prostate cancer. Neoadjuvant…”
Get full text

Molecular and histopathologic correlates of imaging and biological responses to neoadjuvant GnRH agonist plus enzalutamide for high risk prostate cancer by Sowalsky, Adam G., Wilkinson, Scott, Ye, Huihui, VanderWeele, David James, Turkbey, Baris, Hennigan, S. Thomas, Atway, Rayann, Trostel, Shana Y., Lake, Ross, Karzai, Fatima, Harmon, Stephanie, Chun, Guinevere, Kelly, Kathleen, Pinto, Peter A., Choyke, Peter L., Dahut, William L.

“…Abstract only 34 Background: AR directed therapies are standard of care for metastatic prostate cancer, and their use for high-risk localized disease may…”
Get full text

Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer by Chen, Gang, VanderWeele, David James, Karzai, Fatima, Bilusic, Marijo, Al Harthy, Munjid, Arlen, Philip M., Rosner, Inger L., Chun, Guinevere, Owens, Helen, Couvillon, Anna, Hankin, Amy, Williams, Monique, Cordes, Lisa M., Figg, William Douglas, Gulley, James L., Dahut, William L., Madan, Ravi Amrit

“…Abstract only 241 Background: Docetaxel is a standard of care for mCSPC. Enzalutamide and abiraterone have been proven to improve survival in metastatic…”
Get full text

A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC) by Al Harthy, Munjid, Madan, Ravi Amrit, Karzai, Fatima, Petrylak, Daniel Peter, Kim, Joseph W., Arlen, Philip M., Theoret, Marc Robert, Marte, Jenn, Bilusic, Marijo, Couvillon, Anna, Chun, Guinevere, Owens, Helen, Hankin, Amy, Cordes, Lisa M., Figg, William Douglas, Gulley, James L., Dahut, William L.

“…Abstract only 173 Background: A phase I study of Cabozantinib (C) in combination with docetaxel (D) and prednisone (P) in patients (pts) with mCRPC determined…”
Get full text

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer by Madan, Ravi A., Karzai, Fatima H., Ning, Yang‐Min, Adesunloye, Bamidele A., Huang, Xuan, Harold, Nancy, Couvillon, Anna, Chun, Guinevere, Cordes, Lisa, Sissung, Tristan, Beedie, Shaunna L., Dawson, Nancy A., Theoret, Marc R., McLeod, David G., Rosner, Inger, Trepel, Jane B., Lee, Min‐Jung, Tomita, Yusuke, Lee, Sunmin, Chen, Clara, Steinberg, Seth M., Arlen, Philip M., Gulley, James L., Figg, William D., Dahut, William L.

“…Objective To determine the safety and clinical efficacy of two anti‐angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. Patients…”
Get full text

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors by Blumenthal, Gideon M, Gills, Joell J, Ballas, Marc S, Bernstein, Wendy B, Komiya, Takefumi, Dechowdhury, Roopa, Morrow, Betsy, Root, Hyejeong, Chun, Guinevere, Helsabeck, Cynthia, Steinberg, Seth M, LoPiccolo, Jaclyn, Kawabata, Shigeru, Gardner, Erin R, Figg, William D, Dennis, Phillip A

“…Nelfinavir is an HIV protease inhibitor being repurposed as an anti-cancer agent in preclinical models and in small oncology trials, yet the MTD of nelfinavir…”
Get full text

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer by Komiya, Takefumi, Memmott, Regan M., Blumenthal, Gideon M., Bernstein, Wendy, Ballas, Marc S., De Chowdhury, Roopa, Chun, Guinevere, Peer, Cody J., Figg, William D., Liewehr, David J., Steinberg, Seth M., Giaccone, Giuseppe, Szabo, Eva, Kawabata, Shigeru, Tsurutani, Junji, Rajan, Arun, Dennis, Phillip A.

Get full text

EGFR mutations in Latinos from the United States and Latin America by Lopez-Chavez, Ariel, Evbuomwan, Moses, Xi, Liqiang, Chun, Guinevere, Vidaurre, Tatiana, Arrieta, Oscar, Oblitas, George, Oton, Ana Belen, Calvo, Alejandro R., Rajan, Arun, Amarapurkar, Pooja, Raffeld, Mark, Steinberg, Seth M., Arze-Aimaretti, Lorena, Giaccone, Giuseppe

“…Abstract only…”
Get full text